Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Radiofrequency ablation Stories

2013-03-14 11:04:00

Treating varicose veins with vein-stripping surgery is associated with higher costs than closing the veins with heat, according to a study at Henry Ford Hospital in Detroit. "Cost-effectiveness is an important factor to consider when comparing different treatments for varicose vein disease," says Judith C. Lin, M.D., vascular surgeon and lead author of the study. "And these two types of treatment have similar effectiveness." The study will be presented March 13 at the 41st Annual...

2013-02-05 20:21:09

LAWRENCEVILLE, N.J., Feb. 5, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that Zheijang HISUN Pharmaceutical Company (HISUN) does not plan to pursue the exclusive option to license ThermoDox® for the Greater China market. Accordingly, the parties will not enter into the exclusive license agreement, and Celsion will not receive nor will it require any future payment for the option or license, as contemplated in the Exclusive Option Agreement announced on January...

2013-01-31 08:29:54

LAWRENCEVILLE, N.J., Jan. 31, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer. Specifically, Celsion has determined, after conferring with its independent Data Monitoring Committee (DMC) that the HEAT Study...

2013-01-30 16:25:14

LAWRENCEVILLE, N.J., Jan. 30, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Thursday, January 31, 2013 to present the top-line results from its pivotal Phase III HEAT Study with ThermoDox® in combination with radiofrequency ablation (RFA) in patients with intermediate hepatocellular carcinoma (HCC) versus those patients receiving...

2013-01-22 08:30:45

LAWRENCEVILLE, N.J. and TAIZHOU CITY, China, Jan. 22, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, and Zhejiang Hisun Pharmaceutical Company Ltd. (SSE Code: 600267), a leading Chinese pharmaceutical company, today announced that they have entered into a technology development agreement for ThermoDox® for the greater China territory. Under the terms of the agreement, Hisun will pay $5 million to Celsion immediately, while Celsion...

2013-01-07 12:28:32

Cancer Treatment Centers of America(®) at Midwestern Regional Medical Center is the first cancer hospital in Illinois to perform a NanoKnife(®) Procedure CHICAGO, Jan. 7, 2013 /PRNewswire-USNewswire/ -- Interventional radiologists at Cancer Treatment Centers of America® (CTCA) at Midwestern Regional Medical Center (Midwestern) performed the first Nanoknife procedure in Illinois, using electricity to target hard to access tumors. The technology, called...

2012-11-26 08:25:06

FRANKFURT, Germany, Nov. 26, 2012 /PRNewswire/ -- The Department of Nuclear Medicine at the Frankfurt University Hospital recently became the first European hospital to use microwaves to ablate thyroid nodules. The success of the new treatment comes as great news for the nearly 20 percent of Germans who have one or more thyroid nodules. In those over 65 years of age, nearly every second person is affected by a thyroid disorder. The enlargement of the thyroid node can be very unpleasant...

2012-09-06 02:32:00

MARLBOROUGH, Mass., Sept. 6, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces new data showing pulmonary vein isolation (PVI) with its technology leads to a 99% acute success rate and up to an 82% chronic success rate at 12 months follow-up. In addition, the research indicates the HeartLight laser balloon technology resulted in improved long-term outcomes after a single procedure...

2012-07-26 06:23:57

In laboratory study, University of Michigan develops cell-specific technique using photodynamic therapy and nanotechnology for more precise cardiac ablation ANN ARBOR, Mich., July 26, 2012 /PRNewswire-USNewswire/ -- University of Michigan heart researchers are shedding light on a safer method for steadying an abnormal heart rhythm that prevents collateral damage to healthy cells. Irregular heart rhythms, or arrhythmias, set the stage for a common, debilitating disorder called...

2012-07-25 06:37:53

By: Katie Williams, Ivanhoe Health Correspondent (Ivanhoe Newswire)- Researchers have completed the first study of a procedure which uses three dimensional maps to determine the location of electrical signals in children´s hearts. This could help cardiologists correct rapid heart rhythms in young patients. Children who have atrioventricular nodal reentrant tachycardia, or AVNRT, suffer from disruptions in the heart's electrical system that causes sudden rapid heart rates. Patients...